Braidwell’s Centessa Pharmaceuticals CNTA Stock Holding History

Braidwell’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,986,768	Closed	-$78.9M	–	93
2026 Q1	$78.9M	Sell	1,986,768 -201,552	-9%	-$5.16M	2.63%	7
2025 Q4	$54.7M	Buy	+2,188,320	New	+$55.4M	1.75%	16

Braidwell's CNTA Position: Q2 2026 in Review

Braidwell sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 1,986,768 shares — an estimated $78.9M sold.

Braidwell first reported a position in CNTA in Q4 2025 and held it in 2 quarters. The position peaked at $78.9M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Braidwell reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Braidwell sold 1,986,768 Centessa Pharmaceuticals shares in Q2 2026, an estimated $78.9M.
Braidwell first reported a position in Centessa Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Braidwell's Centessa Pharmaceuticals position peaked at $78.9M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.